**Important Changes to Coverage for Hepatitis C Agents**

December 4, 2017

Dear Medicaid Provider,

Effective 1/1/18, the Department of Vermont Health Access (DVHA), in conjunction with Change Healthcare, is making changes to its clinical criteria for approval of direct acting antiviral agents used in the treatment of Hepatitis C. These agents include but are not limited to: Daklinza® (daclatasvir), Epclusa® (sofosbuvir/velpatasvir), Harvoni® (ledipasvir/sofosbuvir), Mavyret® (glecaprevir/pibrentasvir), Sovaldi® (sofosbuvir), Technivie® (ombitasvir, paritaprevir, ritonavir), Viekira XR® (ombitasvir, paritaprevir, ritonavir, dasabuvir), Vosevi® (sofosbuvir/velpatasvir/voxilaprevir), and Zepatier® (elbasvir/grazoprevir). These changes resulted from review of AASLD and IDSA guidelines, and DVHA’s Drug Utilization Review Advisory Board recommendations.

Previously, there was a requirement that the member have a documented Metavir fibrosis score of F2, F3 or F4 to qualify for treatment with these drugs. Approval will now be considered in individuals with ANY Metavir fibrosis score, including F0 and F1. Direct Acting Antivirals will continue to require prior authorization to ensure the patient meets clinical criteria and that the most cost effective, clinically appropriate regimen is utilized. Preferred agents are Epclusa®, Mavyret®, and Zepatier®. Clinical documentation supporting the use of a non-preferred agent or regimen must be submitted with the prior authorization.

Due to the complexity and variety of treatment options and potential for drug interactions, the requirement that the prescriber is, or has consulted with, a gastroenterologist, hepatologist, ID specialist or other Hepatitis specialist will remain in place. Consult must be within the past year and include documentation regarding the requested regimen.

The changes described above are incorporated into the Prior Authorization form and DVHA’s Preferred Drug List (PDL) available on the DVHA provider website [http://dvha.vermont.gov/for-providers/](http://dvha.vermont.gov/for-providers/). Please contact the Change Healthcare Provider Helpdesk at 1-844-679-5363 if you have any questions about these changes.

Thank you for your continued support of Vermont’s clinical pharmacy programs.

Nancy J. Hogue, BS, Pharm.D.

Director of Pharmacy Services